Standard BioTools PE Ratio 2010-2025 | LAB
Current and historical p/e ratio for Standard BioTools (LAB) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Standard BioTools PE ratio as of July 04, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Standard BioTools PE Ratio Historical Data | |||
---|---|---|---|
Date | Stock Price | TTM Net EPS | PE Ratio |
2025-07-03 | 1.35 | 0.00 | |
2025-03-31 | 1.08 | $-0.35 | 0.00 |
2024-12-31 | 1.75 | $-0.55 | 0.00 |
2024-09-30 | 1.93 | $-0.71 | 0.00 |
2024-06-30 | 1.77 | $-0.91 | 0.00 |
2024-03-31 | 2.71 | $-1.01 | 0.00 |
2023-12-31 | 2.21 | $-0.95 | 0.00 |
2023-09-30 | 2.90 | $-0.96 | 0.00 |
2023-06-30 | 1.93 | $-1.06 | 0.00 |
2023-03-31 | 1.95 | $-1.66 | 0.00 |
2022-12-31 | 1.17 | $-2.44 | 0.00 |
2022-09-30 | 1.10 | $-2.30 | 0.00 |
2022-06-30 | 1.60 | $-2.11 | 0.00 |
2022-03-31 | 3.59 | $-1.52 | 0.00 |
2021-12-31 | 3.92 | $-0.78 | 0.00 |
2021-09-30 | 6.59 | $-0.90 | 0.00 |
2021-06-30 | 6.16 | $-0.80 | 0.00 |
2021-03-31 | 4.52 | $-0.75 | 0.00 |
2020-12-31 | 6.00 | $-0.73 | 0.00 |
2020-09-30 | 7.43 | $-0.67 | 0.00 |
2020-06-30 | 4.01 | $-0.78 | 0.00 |
2020-03-31 | 2.54 | $-0.80 | 0.00 |
2019-12-31 | 3.48 | $-1.01 | 0.00 |
2019-09-30 | 4.63 | $-1.19 | 0.00 |
2019-06-30 | 12.32 | $-1.38 | 0.00 |
2019-03-31 | 13.29 | $-1.60 | 0.00 |
2018-12-31 | 8.62 | $-1.50 | 0.00 |
2018-09-30 | 7.49 | $-1.41 | 0.00 |
2018-06-30 | 5.96 | $-1.49 | 0.00 |
2018-03-31 | 5.84 | $-1.65 | 0.00 |
2017-12-31 | 5.89 | $-1.90 | 0.00 |
2017-09-30 | 5.04 | $-2.24 | 0.00 |
2017-06-30 | 4.04 | $-2.46 | 0.00 |
2017-03-31 | 5.69 | $-2.52 | 0.00 |
2016-12-31 | 7.28 | $-2.62 | 0.00 |
2016-09-30 | 8.01 | $-2.46 | 0.00 |
2016-06-30 | 9.03 | $-2.10 | 0.00 |
2016-03-31 | 8.07 | $-1.99 | 0.00 |
2015-12-31 | 10.81 | $-1.86 | 0.00 |
2015-09-30 | 8.11 | $-1.80 | 0.00 |
2015-06-30 | 24.20 | $-1.97 | 0.00 |
2015-03-31 | 42.10 | $-1.89 | 0.00 |
2014-12-31 | 33.73 | $-1.90 | 0.00 |
2014-09-30 | 24.50 | $-1.66 | 0.00 |
2014-06-30 | 29.40 | $-1.34 | 0.00 |
2014-03-31 | 44.07 | $-1.05 | 0.00 |
2013-12-31 | 38.28 | $-0.62 | 0.00 |
2013-09-30 | 21.94 | $-0.61 | 0.00 |
2013-06-30 | 17.46 | $-0.62 | 0.00 |
2013-03-31 | 18.51 | $-0.68 | 0.00 |
2012-12-31 | 14.31 | $-0.87 | 0.00 |
2012-09-30 | 17.00 | $-0.90 | 0.00 |
2012-06-30 | 15.04 | $-0.94 | 0.00 |
2012-03-31 | 15.73 | $-1.08 | 0.00 |
2011-12-31 | 13.16 | $-2.35 | 0.00 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Medical Information Systems | $0.513B | $0.174B |
Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Veeva Systems (VEEV) | United States | $46.456B | 59.10 |
Doximity (DOCS) | United States | $11.587B | 53.64 |
Hims & Hers Health (HIMS) | United States | $10.739B | 111.58 |
Tempus AI (TEM) | United States | $10.555B | 0.00 |
IRhythm Technologies (IRTC) | United States | $4.548B | 0.00 |
Inspire Medical Systems (INSP) | United States | $3.789B | 59.21 |
Hinge Health (HNGE) | United States | $3.638B | 0.00 |
Privia Health (PRVA) | United States | $2.696B | 184.25 |
Enovis (ENOV) | United States | $1.922B | 10.72 |
Phreesia (PHR) | United States | $1.725B | 0.00 |
10x Genomics (TXG) | United States | $1.602B | 0.00 |
Schrodinger (SDGR) | United States | $1.550B | 0.00 |
Azenta (AZTA) | United States | $1.521B | 70.70 |
Omnicell (OMCL) | United States | $1.398B | 24.66 |
Evolent Health (EVH) | United States | $1.384B | 117.90 |
Clover Health Investments (CLOV) | United States | $1.303B | 0.00 |
Claritev (CTEV) | United States | $0.747B | 0.00 |
Fulgent Genetics (FLGT) | United States | $0.611B | 0.00 |
Veradigm (MDRX) | United States | $0.525B | 0.00 |
Butterfly Network (BFLY) | United States | $0.480B | 0.00 |
Talkspace (TALK) | United States | $0.463B | 138.50 |
Outset Medical (OM) | United States | $0.370B | 0.00 |
TruBridge (TBRG) | United States | $0.343B | 761.67 |
Health Catalyst (HCAT) | United States | $0.283B | 0.00 |
Nyxoah SA (NYXH) | Belgium | $0.265B | 0.00 |
SOPHiA GENETICS SA (SOPH) | Switzerland | $0.199B | 0.00 |
KORU Medical Systems (KRMD) | United States | $0.167B | 0.00 |
American Well (AMWL) | United States | $0.133B | 0.00 |
EUDA Health Holdings (EUDA) | Singapore | $0.126B | 0.00 |
Pulmonx (LUNG) | United States | $0.112B | 0.00 |
CareCloud (CCLD) | United States | $0.104B | 3.97 |
MDxHealth SA (MDXH) | Belgium | $0.104B | 0.00 |
Insight Molecular Diagnostics (IMDX) | United States | $0.082B | 0.00 |
111 (YI) | China | $0.064B | 0.00 |
ImmunoPrecise Antibodies (IPA) | Canada | $0.060B | 0.00 |
P3 Health Partners (PIII) | United States | $0.046B | 0.00 |
HeartBeam (BEAT) | United States | $0.044B | 0.00 |
Zepp Health (ZEPP) | Netherlands | $0.043B | 0.00 |
Zhongchao (ZCMD) | China | $0.030B | 0.00 |
Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
Precipio (PRPO) | United States | $0.018B | 0.00 |
Bullfrog AI Holdings (BFRG) | United States | $0.015B | 0.00 |
Healthcare Triangle (HCTI) | United States | $0.010B | 0.00 |
Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
Movano (MOVE) | United States | $0.005B | 0.00 |
HeartSciences (HSCS) | United States | $0.004B | 0.00 |
Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
Evaxion - (EVAX) | Denmark | $0.003B | 0.00 |
Mobile-health Network Solutions (MNDR) | Singapore | $0.003B | 0.00 |
Future Health ESG (FHLT) | United States | $0.000B | 0.00 |